ClinConnect ClinConnect Logo
Search / Trial NCT02337244

Zimmer POLAR Persona - TKA (EMEA Study)

Launched by ZIMMER, GMBH · Jan 8, 2015

Trial Information

Current as of April 25, 2025

Active, not recruiting

Keywords

Osteoarthritis Rheumatoid Arthritis Traumatic Arthritis Polyarthritis Total Knee Arthroplasty

ClinConnect Summary

The Zimmer POLAR Persona study is looking at how well a specific type of knee implant, known as the Persona knee implant, works for people who need a total knee replacement due to severe knee pain and disability caused by conditions like osteoarthritis or rheumatoid arthritis. The main goals of this study are to find out how long the implant lasts, how safe it is, and how it improves patients' overall pain, function, and quality of life.

To participate in this study, individuals must be between 18 and 75 years old and have a medical condition that qualifies them for a total knee replacement. This includes those with severe knee pain due to arthritis or other related issues. Participants will undergo scheduled procedures and follow-up evaluations to monitor their progress. It’s important to note that individuals with certain medical conditions, such as infections in the joint or insufficient bone structure, or those who have had previous knee surgeries on the same knee, will not be eligible for this trial.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patient 18-75 years of age, inclusive.
  • * Patient qualifies for primary total knee arthroplasty based on physical exam and medical history, including diagnosis of severe knee pain and disability due to at least one of the following:
  • rheumatoid arthritis, osteoarthritis, traumatic arthritis, polyarthritis;
  • collagen disorders and/or avascular necrosis of the femoral condyle;
  • post-traumatic loss of joint configuration, particularly when there is patellofemoral erosion, dysfunction or prior patellectomy;
  • moderate valgus, varus, or flexion deformities;
  • the salvage of previously failed surgical attempts that did not include partial or total knee arthroplasty of the ipsilateral knee.
  • Patient is willing and able to complete scheduled study procedures and follow-up evaluations.
  • Independent of study participation, patient is a candidate for commercially available Zimmer Persona knee implants implanted in accordance with product labeling.
  • Exclusion Criteria:
  • Patient is currently participating in any other surgical intervention studies or pain management studies.
  • Previous history of infection in the affected joint and/or other local/systemic infection that may affect the prosthetic joint.
  • Insufficient bone stock on femoral or tibial surfaces.
  • Skeletal immaturity.
  • Neuropathic arthropathy.
  • Osteoporosis or any loss of musculature or neuromuscular disease that compromises the affected limb.
  • Stable, painless arthrodesis in a satisfactory functional position.
  • Severe instability secondary to the absence of collateral ligament integrity.
  • Rheumatoid arthritis accompanied by an ulcer of the skin or a history of recurrent breakdown of the skin.
  • Patient has a known or suspected sensitivity or allergy to one or more of the implant materials.
  • Patient is pregnant or considered a member of a protected population (e.g., prisoner, mentally incompetent, etc.).
  • Patient has previously received partial or total knee arthroplasty for the ipsilateral knee.

About Zimmer, Gmbh

Zimmer GmbH is a leading global medical device company specializing in innovative solutions for musculoskeletal health. With a commitment to advancing orthopedic and reconstructive surgery, Zimmer GmbH focuses on developing and delivering high-quality products and technologies that enhance patient outcomes and improve the quality of life. The company engages in rigorous clinical trials to evaluate the safety and efficacy of its products, ensuring they meet the highest standards of performance and regulatory compliance. Through collaboration with healthcare professionals and ongoing research, Zimmer GmbH strives to be at the forefront of orthopedic innovation, addressing the evolving needs of patients and medical practitioners worldwide.

Locations

Sabadell, , Spain

Zaragoza, , Spain

Clermont Ferrand, , France

Clydebank, , United Kingdom

Wien, , Austria

Montpellier, , France

Braunschweig, , Germany

Heidelberg, , Germany

Delft, , Netherlands

Leeds, Leeds/Uk, United Kingdom

Harrogate, , United Kingdom

Newcastle, , United Kingdom

Patients applied

0 patients applied

Trial Officials

Martin Dominkus, MD

Principal Investigator

Orthopädisches Spital Speising, Wien, Austria

Hendrik Verburg, MD

Principal Investigator

Stichting Research Orthopedie & Reinier de Graaf Groep, Delf, Netherlands

Nicholas London, MD

Principal Investigator

Harrogate and District NHS, Harrogate, England

Stéphane Boisgard, MD

Principal Investigator

CHU de Clermont-Ferrand, Clermont-Ferrand, France

François Canovas, Prof

Principal Investigator

Hospital Lapeyronie, Montpellier

Pere Torner, MD

Principal Investigator

Hospital Parc Tauli, Sabadell

Jon Clarke, MD

Principal Investigator

Golden Jubilee National Hospital, Clydebank

David Deehan, Prof

Principal Investigator

Freeman Hospital, Newcastle

Karl Dieter Heller, Prof

Principal Investigator

HEH Braunschweig

Fritz Thorey, Prof

Principal Investigator

Atos Klinik Heidelberg

Fernando Martinez Delgado, MD

Principal Investigator

Hospital Miguel Servet Zaragoza

Hermant Pandit, Prof

Principal Investigator

University of Leeds

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials